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GOOD MANUFACTURING 
PRACTICE 
Introduction 
 The first WHO draft text on good 
manufacturing practices (GMP) was 
prepared in 1967 by a group of consultants at 
the request of the Twentieth World Health 
Assembly (resolution WHA20.34). It was 
subsequently submitted to the Twenty-first 
World Health Assembly under the title ―Draft 
requirements for good manufacturing 
practice in the manufacture and quality 
control of medicines and pharmaceutical 
specialties‖ and was accepted 
General considerations 
 Licensed pharmaceutical products (marketing authorization) 
should be manufactured only by licensed manufacturers 
(holders of a manufacturing authorization) whose activities 
are regularly inspected by competent national authorities.  
 This guide to GMP shall be used as a standard to justify GMP 
status, which constitutes one of the elements of the WHO 
Certification Scheme on the quality of pharmaceutical 
products moving in international commerce, through the 
assessment of applications for manufacturing authorizations 
and as a basis for the inspection of manufacturing facilities. 
  It may also be used as training material for government 
medicines inspectors, as well as for production, QC and QA 
personnel in the industry. 
General considerations 
 The guide is applicable to operations for the 
manufacture of medicines in their finished 
dosage forms, including large-scale 
processes in hospitals and the preparation of 
supplies for use in clinical trials. 
 The good practices outlined below are to be 
considered general guides, and they may be 
adapted to meet individual needs.  
 The equivalence of alternative approaches to 
QA, however, should be validated. 
General considerations 
 The guide as a whole does not cover safety 
aspects for the personnel engaged in 
manufacture or environmental protection: 
these are normally governed by national 
legislation.  
 A new concept of hazard analysis related to 
the risks in production and personnel safety 
is also newly recommended (Annex 7).  
 The manufacturer should assure the safety of 
workers and take the necessary measures to 
prevent pollution of the external 
environment. 
General considerations 
 International Nonproprietary Names 
(INN) for pharmaceutical substances 
designated by WHO should be used when 
available, together with other designated 
names. 
Quality assurance 
 Principle. QA is a wide-ranging concept 
covering all matters that individually or 
collectively influence the quality of a 
product. It is the totality of the arrangements 
made with the object of ensuring that 
pharmaceutical products are of the quality 
required for their intended use. QA, 
therefore, incorporates GMP and other 
factors, including those outside the scope of 
this guide such as product design and 
development. 
 The system of QA appropriate to the 
manufacture of pharmaceutical products 
should ensure that: 
- pharmaceutical products are designed and 
developed in a way that takes account of the 
requirements of GMP and other associated 
codes such as those of good laboratory 
practice (GLP) and good clinical practice 
(GCP) 
 production and control operations are clearly specified 
in a written form and GMP requirements are adopted; 
 managerial responsibilities are clearly specified in job 
descriptions; 
 arrangements are made for the manufacture, supply 
and use of the correct starting and packaging 
materials; 
 all necessary controls on starting materials, 
intermediate products, and bulk products and other in-
process controls, calibrations, and validations are 
carried out; 
 the finished product is correctly processed and 
checked, according to the defined procedures; 
 The manufacturer must assume 
responsibility for the quality of the 
pharmaceutical products to ensure that 
they are fit for their intended use, comply 
with the requirements of the marketing 
authorization and do not place patients at 
risk due to inadequate safety, quality or 
efficacy 
 The attainment of this quality objective is the responsibility 
of senior management and requires the participation and 
commitment of staff in many different departments and at all 
levels within the company, the company’s suppliers, and the 
distributors. 
  To achieve the quality objective reliably there must be a 
comprehensively designed and correctly implemented system 
of QA incorporating GMP and QC. It should be fully 
documented and its effectiveness monitored. 
  All parts of the QA system should be adequately staffed with 
competent personnel, and should have suitable and sufficient 
premises, equipment and facilities. 
Good manufacturing practices 
for pharmaceutical products 
 GMP is that part of QA which ensures that 
products are consistently produced and controlled 
to the quality standards appropriate to their 
intended use and as required by the marketing 
authorization. GMP are aimed primarily at 
diminishing the risks inherent in any 
pharmaceutical production. 
 Such risks are essentially of two types: cross-
contamination (in particular of unexpected 
contaminants) and mix ups (confusion) caused by, 
for example, false labels being put on containers. 
 Under GMP: 
 all manufacturing processes are clearly 
defined, systematically reviewed in the light 
of experience, and shown to be capable of 
consistently manufacturing pharmaceutical 
products of the required quality that comply 
with their specifications; 
 qualification and validation are performed; 
 all necessary resources are provided, 
including: 
appropriately qualified and trained 
personnel; 
adequate premises and space; 
suitable equipment and services; 
appropriate materials, containers and labels; 
approved procedures and instructions; 
suitable storage and transport; 
adequate personnel, laboratories and 
equipment for in-process controls; 
 instructions and procedures are written in clear 
and unambiguous language, specifically 
applicable to the facilities provided; 
 operators are trained to carry out procedures 
correctly; 
 records are made (manually and/or by recording 
instruments) during manufacture to show that all 
the steps required by the defined procedures and 
instructions have in fact been taken and that the 
quantity and quality of the product are as 
expected;  
 any significant deviations are fully recorded and 
investigated; 
 records covering manufacture and distribution, 
which enable the complete history of a batch to be 
traced, are retained in a comprehensible and 
accessible form; 
 the proper storage and distribution of the products 
minimizes any risk to their quality; 
 a system is available to recall any batch of product 
from sale or supply; 
 complaints about marketed products are 
examined, the causes of quality defects 
investigated, and appropriate measures taken in 
respect of the defective products to prevent 
recurrence. 
Sanitation and hygiene 
 A high level of sanitation and hygiene should be 
practiced in every aspect of the manufacture of 
medicines products.  
 The scope of sanitation and hygiene covers 
personnel, premises, equipment and apparatus, 
production materials and containers, products for 
cleaning and disinfection, and anything that could 
become a source of contamination to the product.  
 Potential sources of contamination should be 
eliminated through an integrated comprehensive 
programme of sanitation and hygiene. 
Qualification and validation 
 In accordance with GMP, each 
pharmaceutical company should identify 
what qualification and validation work is 
required to prove that the critical aspects 
of their particular operation are controlled. 
 The key elements of a qualification and 
validation programme of a company 
should be clearly defined and documented 
in a validation master plan. 
Qualification and validation 
 Qualification and validation should establish and provide 
documentary evidence that: 
 the premises, supporting utilities, equipment and processes 
have been designed in accordance with the requirements for 
GMP design qualification or DQ); 
 the premises, supporting utilities and equipment have been 
built and installed in compliance with their design 
specifications (installation qualification or IQ); 
 the premises, supporting utilities and equipment operate in 
accordance with their design specifications (operational 
qualification or OQ); 
 a specific process will consistently produce a product meeting 
its predetermined specifications and quality attributes 
(process validation or PV, also called performance 
qualification or PQ). 
 Any aspect of operation, including significant changes 
to the premises, facilities, equipment or processes, 
which may affect the quality of the product, directly 
or indirectly, should be qualified and validated. 
 Qualification and validation should not be considered 
as one-off exercises. An ongoing programme should 
follow their first implementation and should be based 
on an annual review. 
 The commitment to maintain continued validation 
status should be stated in the relevant company 
documentation, such as the quality manual or 
validation master plan. 
 The responsibility of performing validation should 
be clearly defined. 
 Validation studies are an essential part of GMP 
and should be conducted in accordance with 
predefined and approved protocols. 
 A written report summarizing the results recorded 
and the conclusions reached should be prepared 
and stored. 
 Processes and procedures should be established 
on the basis of the results of the validation 
performed. 
 Particular attention should be paid to the 
validation of analytical test methods, automated 
systems and cleaning procedures. 
Personnel 
 All personnel should be aware of the 
principles of GMP that affect them and 
receive initial and continuing training, 
including hygiene instructions, relevant to 
their needs.  
 All personnel should be motivated to 
support the establishment and 
maintenance of high quality standards. 
Personal hygiene 
 All personnel, prior to and during employment, as 
appropriate, should undergo health examinations. 
Personnel conducting visual inspections should 
also undergo periodic eye examinations. 
 All personnel should be trained in the practices of 
personal hygiene 
 Any person shown at any time to have an apparent 
illness or open lesions that may adversely affect 
the quality of products should not be allowed to 
handle starting materials, packaging materials, in-
process materials or medicines products until the 
condition is no longer judged to be a risk. 
Personal hygiene 
 All employees should be instructed and 
encouraged to report to their immediate 
supervisor any conditions (relating to plant, 
equipment or personnel) that they consider may 
adversely affect the products. 
 Direct contact should be avoided between the 
operator’s hands and starting materials, primary 
packaging materials and intermediate or bulk 
product. 
 To ensure protection of the product from 
contamination, personnel should wear clean body 
coverings appropriate to the duties they perform, 
including appropriate hair covering. 
Personal hygiene 
 Used clothes, if reusable, should be stored in separate 
closed containers until properly laundered and, if 
necessary, disinfected or sterilized. 
 Smoking, eating, drinking, chewing, and keeping 
plants, food, drink, smoking material and personal 
medicines should not be permitted in production, 
laboratory and storage areas, or in any other areas 
where they might adversely influence product quality. 
 Personal hygiene procedures including the use of 
protective clothing should apply to all persons 
entering production areas, whether they are temporary 
or full-time employees or nonemployees, e.g. 
contractors’ employees, visitors, senior managers and 
inspectors. 
MANUFACTURE OF STERILE 
MEDICINAL PRODUCTS 
Principle 
 The manufacture of sterile products is subject to 
special requirements in order to minimize risks of 
microbiological contamination, and of particulate and 
pyrogenic contamination.  
 Much depends on the skill, training and attitudes of 
the personnel involved.  
 Quality Assurance is particularly important, and this 
type of manufacture must strictly follow carefully 
established and validated methods of preparation and 
procedure.  
 Sole reliance for sterility or other quality aspects must 
not be placed on any terminal process or finished 
product test. 
 The manufacture of sterile products 
should be carried out in clean areas entry 
to which should be through airlocks for 
personnel and/or for equipment and 
materials.  
 Clean areas should be maintained to an 
appropriate cleanliness standard and 
supplied with air which has passed 
through filters of an appropriate 
efficiency. 
 The various operations of component 
preparation, product preparation and 
filling should be carried out in separate 
areas within the clean area.  
 Manufacturing operations are divided into 
two categories; firstly those where the 
product is terminally sterilized, and 
secondly those which are conducted 
aseptically at some or all stages. 
 Clean areas for the manufacture of sterile 
products are classified according to the 
required characteristics of the 
environment.  
 Each manufacturing operation requires an 
appropriate environmental cleanliness 
level in the operational state in order to 
minimize the risks of particulate or 
microbial contamination of the product or 
materials being handled. 
 For the manufacture of sterile medicinal 
products 4 grades can be distinguished: 
- Grade A 
- Grade B 
- Grade C and D 
 Grade A: The local zone for high risk 
operations, e.g. filling zone, stopper bowls, 
open ampoules and vials, making aseptic 
connections.  
 Normally such conditions are provided by a 
laminar air flow work station.  
 Laminar air flow systems should provide a 
homogeneous air speed in a range of 0.36 – 
0.54 m/s (guidance value) at the working 
position in open clean room applications. 
The maintenance of laminarity should be 
demonstrated and validated 
 Grade B: For aseptic preparation and 
filling, this is the background environment 
for the grade A zone. 
 Grade C and D: Clean areas for carrying 
out less critical stages in the manufacture 
of sterile products.  
Terminally sterilized products 
 Preparation of components and most products 
should be done in at least a grade D environment 
in order to give low risk of microbial and 
particulate contamination, suitable for filtration 
and sterilization.  
 Where the product is at a high or unusual risk of 
microbial contamination, (for example, because 
the product actively supports microbial growth or 
must be held for a long period before sterilization 
or is necessarily processed not mainly in closed 
vessels), then preparation should be carried out in 
a grade C environment. 
Terminally sterilized products 
 Filling of products for terminal sterilization 
should be carried out in at least a grade C 
environment 
 Where the product is at unusual risk of 
contamination from the environment, for 
example because the filling operation is slow 
or the containers are wide-necked or are 
necessarily exposed for more than a few 
seconds before sealing, the filling should be 
done in a grade A zone with at least a grade 
C background. 
Aseptic preparation 
 Components after washing should be handled in at 
least a grade D environment. Handling of sterile 
starting materials and components, unless 
subjected to sterilization or filtration through a 
micro-organism-retaining filter later in the 
process, should be done in a grade A environment 
with grade B background. 
 Preparation of solutions which are to be sterile 
filtered during the process should be done in a 
grade C environment; if not filtered, the 
preparation of materials and products should be 
done in a grade A environment with a grade B 
background. 
Aseptic preparation 
 Handling and filling of aseptically 
prepared products should be done in a 
grade A environment with a grade B 
background. 
 Prior to the completion of stoppering, 
transfer of partially closed containers, as 
used in freeze drying should be done 
either in a grade A environment with 
grade B background or in sealed transfer 
trays in a grade B environment. 
Personnel 
 Only the minimum number of personnel required 
should be present in clean areas 
 All personnel (including those concerned with 
cleaning and maintenance) employed in such 
areas should receive regular training in disciplines 
relevant to the correct manufacture of sterile 
products.  
 This training should include reference to hygiene 
and to the basic elements of microbiology. When 
outside staff who have not received such training 
(e.g. building or maintenance contractors) need to 
be brought in, particular care should be taken over 
their instruction and supervision. 
Personnel 
 High standards of personal hygiene and 
cleanliness are essential. 
 Wristwatches, make-up and jewellery should not 
be worn in clean areas 
 Changing and washing should follow a written 
procedure designed to minimize contamination of 
clean area clothing or carry-through of 
contaminants to the clean areas. 
 The clothing and its quality should be appropriate 
for the process and the grade of the working area. 
It should be worn in such a way as to protect the 
product from contamination 
 
 
Personnel 
 The description of clothing required for each grade is given below: 
 Grade D: Hair and, where relevant, beard should be covered. A 
general protective suit and appropriate shoes or overshoes should be 
worn. Appropriate measures should be taken to avoid any 
contamination coming from outside the clean area. 
 Grade C: Hair and where relevant beard and moustache should be 
covered. A single or two-piece trouser suit, gathered at the wrists 
and with high neck and appropriate shoes or overshoes should be 
worn. They should shed virtually no fibres or particulate matter. 
 Grade A/B: Headgear should totally enclose hair and, where 
relevant, beard and moustache; it should be tucked into the neck of 
the suit; a face mask should be worn to prevent the shedding of 
droplets. Appropriate sterilized, non-powdered rubber or plastic 
gloves and sterilized or disinfected footwear should be worn. 
Trouser-legs should be tucked inside the footwear and garment 
sleeves into the gloves. The protective clothing should shed 
virtually no fibres or particulate matter and retain particles shed by 
the body. 

Premises 
 In clean areas, all exposed surfaces should be smooth, 
impervious and unbroken in order to minimize the shedding 
or accumulation of particles or micro-organisms and to 
permit the repeated application of cleaning agents, and 
disinfectants where used. 
 To reduce accumulation of dust and to facilitate cleaning 
there should be no uncleanable recesses and a minimum of 
projecting ledges, shelves, cupboards and equipment.  
 Doors should be designed to avoid those uncleanable 
recesses; sliding doors may be undesirable for this reason. 
 False ceilings should be sealed to prevent contamination from 
the space above them. 
 Pipes and ducts and other utilities should be installed so that 
they do not create recesses, unsealed openings and surfaces 
which are difficult to clean. 
Premises 
 Sinks and drains should be prohibited in grade A/B areas used 
for aseptic manufacture. 
 Changing rooms should be designed as airlocks and used to 
provide physical separation of the different stages of 
changing and so minimize microbial and particulate 
contamination of protective clothing.  
 Both airlock doors should not be opened simultaneously. 
 A filtered air supply should maintain a positive pressure and 
an air flow relative to surrounding areas of a lower grade 
under all operational conditions and should flush the area 
effectively. 
 It should be demonstrated that air-flow patterns do not 
present a contamination risk 
 A warning system should be provided to indicate failure in 
the air supply. 
Sterilization 
 All sterilization processes should be 
validated. Particular attention should be 
given when the adopted sterilization method 
is not described in the current edition of the 
European Pharmacopoeia, or when it is used 
for a product which is not a simple aqueous 
or oily solution.  
 Where possible, heat sterilization is the 
method of choice.  
 In any case, the sterilization process must be 
in accordance with the marketing and 
manufacturing authorizations. 
Sterilization 
 Before any sterilization process is adopted its 
suitability for the product and its efficacy in 
achieving the desired sterilizing conditions in 
all parts of each type of load to be processed 
should be demonstrated by physical 
measurements and by biological indicators 
where appropriate. The validity of the 
process should be verified at scheduled 
intervals, at least annually, and whenever 
significant modifications have been made to 
the equipment. Records should be kept of the 
results. 
 For effective sterilization the whole of the 
material must be subjected to the required 
treatment and the process should be 
designed to ensure that this is achieved. 
 Validated loading patterns should be 
established for all sterilization processes. 
 Biological indicators should be considered 
as an additional method for monitoring 
the sterilization. 
PHARMACEUTICAL 
MICROBIOLOGY 
Introduction 
 Pharmaceutical microbiology laboratories 
may be involved in: 
— sterility testing; 
— detection, isolation, enumeration and 
identification of microorganisms (bacteria, 
yeast and moulds) and testing for bacterial 
endotoxins in different materials (e.g. starting 
materials, water), products, surfaces, garments 
and the environment; 
— assay using microorganisms as part of the 
test system. 
Personnel 
 Microbiological testing should be performed and supervised 
by an experienced person, qualified in microbiology or 
equivalent.  
 Staff should have basic training in microbiology and relevant 
practical experience before being allowed to perform work 
covered by the scope of testing. 
 The laboratory management should ensure that all personnel 
have received adequate training for the competent 
performance of tests and operation of equipment. 
 Personnel should be trained in necessary procedures for 
containment of microorganisms within the laboratory facility. 
 Personnel should be trained in safe handling of 
microorganisms 
Environment 
Premises 
 Microbiology laboratories and certain support 
equipment (e.g. autoclaves and glassware) should 
be dedicated and separated from other areas, 
especially from production areas. 
 Microbiology laboratories should be designed to 
suit the operations to be carried out in them. 
 There should be separate air supply to laboratories 
and production areas. 
 Access to the microbiological laboratory should 
be restricted to authorized personnel: 
Environment 
 Premises 
 Personnel should be made aware of: 
— the appropriate entry and exit procedures 
including gowning; 
— the intended use of a particular area; 
— the restrictions imposed on working within 
such areas; 
— the reasons for imposing such restrictions; 
— the appropriate containment levels. 
Environment 
Cleaning, disinfection and hygiene 
 There should be a documented cleaning 
and disinfection programme. 
 Results of environmental monitoring 
should be considered where relevant. 
 There should be a procedure for dealing 
with spillages. 
 Adequate hand-washing and hand-
disinfection facilities should be available. 
Validation of test methods 
 Standard (pharmacopoeia) test methods are 
considered to be validated. 
 Test methods not based on compendia or other 
recognized references should be validated before use. 
The validation should comprise, where appropriate, 
determining accuracy, precision, specificity, limit of 
detection, limit of quantitation, linearity and 
robustness. 
 Potentially inhibitory effects from the sample should 
be taken into account when testing different types of 
sample.  
 The results should be evaluated with appropriate 
statistical methods, e.g. as described in the national, 
regional or international pharmacopoeias. 
Equipment 
 Each item of equipment, instrument or 
other device used for testing, verification 
and calibration should be uniquely 
identified. 
 As part of its quality system, a laboratory 
should have a documented program for 
the qualification, calibration, performance 
verification, maintenance and a system for 
monitoring the use of its equipment. 
Equipment 
Calibration, performance verification and 
monitoring of use 
 The date of calibration and servicing and the 
date when recalibration is due should be 
clearly indicated on a label attached to the 
instrument 
 The frequency of calibration and 
performance verification will be determined 
by documented experience and will be based 
on need, type and previous performance of 
the equipment 
 
 
Reagents and culture media 
 Laboratories should ensure that the quality of 
a reagents and media used is appropriate for 
the test concerned. 
 Laboratories should verify the suitability of 
each batch of reagents critical for the test, 
initially and during its shelf-life. 
 Media may be prepared in-house or 
purchased either partially or fully prepared. 
Vendors of purchased media should be 
approved and qualified. 
 Labelling 
 Laboratories should ensure that all reagents 
(including stock solutions), media, diluents 
and other suspending fluids are adequately 
labelled to indicate, as appropriate, identity, 
concentration, storage conditions, 
preparation date, validated expiry date and/or 
recommended storage periods. The person 
responsible for preparation should be 
identifiable from records. 
 Organism resuscitation 
 Organism resuscitation is required where test 
methodologies may produce sublethally 
injured cells. For example, exposure to: 
— injurious effects of processing, e.g. heat; 
— antimicrobial agents; 
— preservatives; 
— extremes of osmotic pressure; and 
— extremes of pH. 
 Organism resuscitation may be achieved 
by: 
— exposure to a liquid media like a simple 
salt solution at room temperature for 2 
hours; 
— exposure to a solid repair medium for 4–
6 hours. 
Reference materials and reference 
cultures 
International standards and pharmacopoeia reference substances 
 Reference materials and certified reference materials are generally 
used in a microbiological laboratory to qualify, verify and calibrate 
equipment. 
 Whenever possible these reference materials should be used in 
appropriate matrices. 
 International standards and pharmacopoeia reference substances are 
employed, for example, to: 
— determine potency or content; 
— validate methods; 
— enable comparison of methods; 
— perform positive controls;  
— perform growth promotion tests. 
 If possible reference materials should be used in appropriate 
matrices. 
